New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
12:11 EDTLLY, BTU, EMC, YHOO, STX, PFE, VLO, VMW, KERX, SANM, LXK, BSX, DHI, F, HES, BMCOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday in spite of a consumer confidence reading that plunged to its lowest level in more than a year after workers assessed the impact of increased payroll taxes. Though the Nasdaq was marginally lower near noon, the Dow's move higher pushed it back near its 14,164.53 all time high... ECONOMIC EVENTS: In the U.S., the November S&P/Case-Shiller 20-city Home-Prices Index was up a seasonally adjusted 0.6% from the prior month, versus expectations for a 0.7% increase. On a year-over-year basis, the 20-city index rose 5.5%, which was nearly in-line with consensus. The Consumer Confidence reading for January fell to 58.6, versus expectations for a smaller decline to 64.0... COMPANY NEWS: Ford (F) reported quarterly results that widely beat expectations on both the top and bottom lines, but shares fell nearly 6% after the company also said it now expects to lose about $2B in Europe this year... Among others reporting earnings last night and this morning, advancers included DR Horton (DHI), Valero (VLO), Peabody Energy (BTU), Boston Scientific (BSX), Pfizer (PFE) and Eli Lilly (LLY); decliners included Lexmark (LXK), Seagate (STX), BMC Software (BMC), Yahoo! (YHOO) and Sanmina (SANM)... MAJOR MOVERS: Among the notable gainers was Hess (HES), which added almost another 10% after being up more than 6% yesterday. Shareholder Elliott Management, which is seeking to elect five directors to Hess' board, said that if managed appropriately, the equity value of Hess could be up to $126 per share. Also higher for a second straight session were shares of Keryx Biopharmaceuticals (KERX), up over 33% today after the price target on its shares was raised by at least three more firms. Among the noteworthy losers was VMware (VMW), which fell 20% and was downgraded by at least six firms following its Q4 results and FY13 guidance. Also lower by more than 4% were shares of EMC (EMC), which holds a majority ownership stake in VMware. Like VMware, EMC reported stronger than expected quarterly results but issued a cautious outlook for the year ahead... INDICES: Near noon, the Dow was up 55.11, or 0.40%, to 13,937.04; the Nasdaq was down 2.75, or 0.09%, to 3,151.55; and the S&P 500 was up 4.50, or 0.30%, to 1,504.68.
News For F;VMW;EMC;DHI;VLO;BTU;BSX;PFE;LLY;LXK;STX;BMC;SANM;YHOO;HES;KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 10, 2014
06:36 EDTEMCNetApp initiated with a Neutral at JPMorgan
JPMorgan sees a lack of catalysts for storage earnings in 2015 and views the valuations of both NetApp (NTAP) and (EMC) as full at current levels. The firm started shares of both companies with Neutral ratings. It has a $43.50 price target for NetApp shares.
06:34 EDTEMCEMC initiated with a Neutral at JPMorgan
JPMorgan sees a lack of catalysts for storage earnings in 2015. The firm started shares of EMC with a Neutral rating and $31 price target.
06:01 EDTBSXBoston Scientific implied volatility of 38 at upper end of index mean range
December 9, 2014
12:22 EDTPFEPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:32 EDTPFEPfizer says in talks with FDA on path forward for Mylotarg
Pfizer announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate MYLOTARG in select adult AML populations. Research was presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, December 6-9. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology, said “In particular, we are encouraged by the significant clinical evidence emerging from large randomized trials, such as AML-19 and ALFA-0701, demonstrating a positive impact of MYLOTARG when added to standard first-line treatment for patients with acute myeloid leukemia. We are engaging in discussions with the U.S. FDA and other health authorities to determine the best path forward for MYLOTARG. In addition, we plan to initiate an expanded access protocol for the therapy by the end of 2014 in the United States in patients with relapsed or refractory acute myeloid leukemia for whom there are no other treatment options.”
10:27 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
09:17 EDTFTeleTech to expand in China through Percepta joint venture
TeleTech Holdings (TTEC) announced plans to expand in China through Percepta, a global joint venture with Ford Motor (F). Providing service and support through all stages of the customer lifecycle, Percepta operates customer contact centers on five continents specifically for the automotive industry.
07:44 EDTPFE, LLYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:41 EDTSTXBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 9 at 10:40 am; not all company presentations may be webcasted. Webcast Link
07:37 EDTFUBS to hold a conference
Subscribe for More Information
07:11 EDTLLYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
11:10 EDTFVolkswagen sees challenging developments continuing for rest of year
Volkswagen (VLKAY) said, “The challenging developments on markets worldwide – above all in Eastern Europe and South America – will continue for the remainder of this year. The Volkswagen Passenger Cars brand handled these challenges successfully during the course of the year, but was not entirely immune to their impact.” Other publicly traded companies in the passenger automotive space include Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), and Toyota (TM).
10:42 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.
08:07 EDTFFord management to meet with UBS
Meeting to be held in Boston on December 8 hosted by UBS.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
07:28 EDTSTXFBN Securities to hold a bus tour
Subscribe for More Information
07:26 EDTBTUPeabody still sees FY14 coal sales volumes 245M-255M tons
Peabody Energy Corporation said in a filing that it reaffirms its prior guidance regarding 2014 coal sales volumes, U.S. revenues per ton, operating costs and expenses per ton and capital spending. Specifically, Peabody continues to target full-year 2014 sales volumes of 245 to 255 million tons, including U.S. sales of 185 to 190 million tons and Australian sales of 36 to 38 million tons. Peabody's targeted 2014 Australian sales volumes include 16 to 17 million tons of metallurgical coal and 12 to 13 million tons of seaborne thermal coal. In the U.S., Peabody continues to project a 2% to 4% decrease in revenues per ton compared to the prior year. Peabody also continues to expect a 1% to 3% decrease in its U.S. operating costs and expenses per ton in 2014 compared to the prior year and 2014 Australian operating costs and expenses of approximately $70 per ton, in addition to 2014 capital spending levels of $200M-$220M.
05:53 EDTBSXStocks with implied volatility movement; BSX BMY
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use